Tuberculosis in patient with psoriasis receiving biologic therapy: Case report
More details
Hide details
Chair and Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Submission date: 2020-06-17
Final revision date: 2020-08-13
Acceptance date: 2020-08-14
Online publication date: 2020-11-04
Corresponding author
Beata Wańczyk-Dręczewska   

Wojska Polskiego 30, 10-292 Olsztyn, Poland. Phone: +48 660547828.
Pol. Ann. Med. 2020;27(2):209-213
The introduction of biological therapy has revolutionized the treatment of psoriasis. Due to its immunosuppressive effect, the following side effects might occur: injection-site reactions, exacerbation of autoimmune diseases, increased risk of malignant tumors and infections, including tuberculosis (TB).

The aim of this report is to present a case of a patient who developed TB during tumornecrosis factor α (TNF-α) inhibitor therapy.

Case study:
A 52-year-old man was admitted to the Dermatology Clinic for re-qualification for biological treatment with adalimumab. The patient was treated with cyclosporin A and lefludomide combined with methotrexate with no effect and the adalimumab therapy was initiated with complete remission of psoriatic lesions. The patient was suspended in the drug program because of TB. TNF-α inhibitor therapy was resumed after antimycobacterial treatment, during which lymphadenopathy was observed and serous TB was confirmed. Three months after the treatment, the patient was rehospitalized because of suspicion of TB relapse. It was decided to requalify the patient for biological therapy after completion of antimycobacterial treatment. Due to the high risk of TB recurrence, switch to the interleukin-17 inhibitor was decided.

Results and discussion:
The proper qualification and thorough testing before biological treatment ensures patients’ safety and satisfactory therapeutic effect. It should be remembered that during longterm therapy with TNF antagonists, both reactivation of latent TB as well as new infection are serious problems. Therefore, regular tests should be performed, especially in countries with high prevalence of this disease.

In patients who develop TB, particularly recurrent, switching to a drug with a different mechanism should be considered.

None declared.
None declared.
Flood KS, Porter ML, Kimball AB. Biologic Treatment for Hidradenitis Suppurativa. Am J Clin Dermatol. 2019;20(5):625–638.
Korzeniewska-Koseła M, Paprota M, Bestry I. Clinical practice – pneumology: 64-year-old woman with pulmonary tuberculosis diagnosed before anti-TNF treatment. Med Prakt. 2016;6:88–93 [in Polish].
Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69(3):522–528.
Chan MJ, Wen YH, Huang YB, et al. Risk of tuberculosis comparison in new users of antitumour necrosis factor-alpha and with existing disease-modifying antirheumatic drug therapy. J Clin Pharm Ther. 2018;43(2):256–264.
Korzeniewska-Koseła M. Tuberculosis and Diseases of the Respiratory System in Poland in 2019. Warszawa: Institute of Tuberculosis and Lung Diseases; 2020 [in Polish].
Chan ED, Bai X, Kartalija M, Orme IM, Ordway DJ. Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease. Am J Respir Cell Mol Biol. 2010;43(4):387–393.
Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench to bedside. J Microbiol Immunol Infect. 2014;47(4):268–274.
Beenhouwer D, Wallis R, Broder M, Furst DE. Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections. J Rheumatol. 2004;31(10):1888–1892.
Bae JY, Lee JI, Kim HL, et al. Disseminated tuberculosis following adalimumab treatment in psoriasis despite negative screening. Int J Dermatol. 2019;58(1):98–100.
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–1104.
Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis. 2006;194(4):486–492.
Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
Snast I, Bercovici E, Solomon-Cohen E, et al. Active tuberculosis in patients with psoriasis receiving biologic therapy: A systematic review. Am J Clin Dermatol. 2019;20(4):483–491.
Korzeniewska-Koseła M. Prevention of tuberculosis in patients treated with tumour necrosis factor antagonists. Reumatologia/Rheumatology. 2010;48(1):4–13 [in Polish].
Augustynowicz-Kopeć E, Demkow U, Grzelewska-Rzymowska I, et al. Guidelines of Polish Respiratory Society concerning diagnosis, treatment and prevention of tuberculosis in adults and in child. Pneumonol Alergol Pol. 2013;81(4):325–379 [in Polish].
Kucharz EJ, Korzeniewska-Koseła M, Kotulska A. Recommendations for prophylaxis and management of tuberculosis in patients treated with TNF-α antagonists. Reumatologia/Rheumatology. 2008;46(2):51–54 [in Polish].
Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of treatment for latent tuberculosis infection in patients with inflammatory bowel disease receiving biologic therapy. Inflamm Bowel Dis. 2018;24(10):2272–2277.
van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98.e84.
Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
Journals System - logo
Scroll to top